Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.60 |
| ▸ | CTSS | P25774 | 7/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
| ▸ | PPARA | Q07869 | 5/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13743658 | 1.00 | CTSK (0.60) | CTSKCTSSPTPN1PPARAPPARG | |
| SCHEMBL4663077 | 1.00 | CTSK (0.60) | CTSKCTSSPTPN1PPARAPPARG | |
| SCHEMBL29401585 | 0.87 | CTSS (0.73) | CTSKCTSSPTPN1PPARAPPARG | |
| SCHEMBL1270141 | 0.87 | CTSS (0.73) | CTSKCTSSPTPN1PPARAPPARG | |
| SCHEMBL270318 | 0.87 | CTSS (0.73) | CTSKCTSSPTPN1PPARAPPARG | |
| SCHEMBL270319 | 0.87 | CTSS (0.73) | CTSKCTSSPTPN1PPARAPPARG | |
| SCHEMBL29907906 | 0.87 | CTSS (0.73) | CTSKCTSSPTPN1PPARAPPARG | |
| SCHEMBL10151226 | 0.86 | CTSK (0.56) | CTSKCTSSPTPN1PPARAPPARG | |
| SCHEMBL12305800 | 0.86 | CTSK (0.56) | CTSKCTSSPTPN1PPARAPPARG | |
| SCHEMBL181807 | 0.85 | CTSK (0.71) | CTSKCTSSPPARAPPARGSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338471-B2 | (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2012-12-25 | — | — | US | disclosed |
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2012-01-19 | — | — | US | disclosed |
| US-8022092-B2 | (2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2011-09-20 | — | — | US | disclosed |
| WO-2007068474-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | CTSK 417/4885CTSS 186/4885PTPN1 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.